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Abstract
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is a major pathogenicity factor
in falciparum malaria that mediates cytoadherence. PfEMP1 is encoded by ~60 var genes per
haploid genome. Most var genes are grouped into 3 subgroups: A, B, and C. Evidence is emerging
that the specific expression of these subgroups has clinical significance. Using field samples from
children from Papua New Guinea with severe, mild, and asymptomatic malaria, we compared
proportions of transcripts of var groups, as determined by quantitative polymerase chain reaction.
We found a significantly higher proportion of var group B transcripts in children with clinical
malaria (mild and severe), whereas a large proportion of var group C transcripts was found in
asymptomatic children. These data from naturally infected children clearly show that major
differences exist in var gene expression between parasites causing clinical disease and those
causing asymptomatic infections. Furthermore, parasites forming rosettes showed a significant up-
regulation of var group A transcripts.
Various factors contribute to the pathologic characteristics of severe malaria, including
cytoadherence (reviewed in [1]). This is the adhesion of late-stage–infected erythrocytes to
various receptors—such as CD36 or intercellular adhesion molecule–1 on the vascular
endothelium, chondroitin sulfate A in the placenta, and complement receptor (CR)–1 on red
blood cells (RBCs; also called “rosetting”)—that leads to microvascular obstructions in
various organs (reviewed in [2]). Cytoadherence is mainly mediated by a family of parasite-
derived polymorphic Plasmodium falciparum antigens on the surface of late-stage–infected
erythrocytes [3]. These P. falciparum erythrocyte membrane proteins (PfEMP1) are large
(200–350 kDa) and antigenically variant. PfEMP1 is structured into different
semiconserved, adhesive domains: Duffy binding–like (DBL) domains and cysteine-rich
interdomain regions (reviewed in [4]).
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In the P. falciparum line 3D7, PfEMP1 is encoded by 1 of 59 var genes [5-8]. Most var
genes can be assigned to 1 of 3 types (var groups A, B, and C), mainly according to their
conserved 5′ upstream sequences [6, 9]. In 3D7, the majority of var genes belongs to the
subtelomerically located var group B, whereas 13 var group C genes are arranged in
chromosome internal clusters. Ten mostly larger, subtelomerically located var genes with a
distinct domain structure belong to var group A [10]. var genes are exclusively expressed
but undergo switching within parasite lineages [11, 12]. Transcripts of several var genes can
be detected within a single host at any time [13, 14].
Various studies have analyzed the association between disease outcome and the binding of
field isolates to endothelial receptors [15-18]. Using agglutination assays, Bull et al. [19]
identified a restricted subset of variant surface antigens (VSAs) involved in severe disease.
This raises the question of whether var group A, B, or C would represent such subsets. We
conducted a case-control study of malaria in Papua New Guinea (PNG) involving 65
children, to study associations between the expression of var group A, B, or C genes and
clinical presentation. We compared the relative contribution of transcripts of each var group,
as determined by quantitative real-time polymerase chain reaction (qPCR), in children with
severe, mild, and asymptomatic malaria. To our knowledge, this is the first study to have
compared the expression of var subgroups and clinical outcome in vivo. We also analyzed
the rosetting capacity of infected erythrocytes, to test whether a certain var gene group
mediates this trait in PNG.
SUBJECTS, MATERIALS, AND METHODS
Population and study design
The study was conducted in the Madang General Hospital, PNG, during the wet season
(February–May) of 2003. P. falciparum malaria is holoendemic in Madang and has
perennial transmission. Infections with P. vivax are also common. Malaria accounts for
15.3% of deaths in children in this hospital, with a case-fatality rate of 3.6% [20]. After
written, informed consent was obtained from parents, venous blood (1 mL) was taken from
14 children (age range, 0.5–6 years) with severe malaria, as defined in accordance with
World Health Organization criteria (2000) [1]. All children had asexual P. falciparum
parasites present, with cerebral malaria, prostration, several convulsions within the
preceding 24 h, or severe anemia (hemoglobin level, <5 g/dL) (table 1). None of the children
died. In addition, 26 children of similar age (±20% of the age of the children with severe
malaria) with mild malaria were enrolled at the hospital and the town clinic of Madang.
Mild malaria was defined as the presence of asexual P. falciparum parasites and an axillary
temperature >37.5°C or symptoms of headache, fever, or myalgia. For children with severe
malaria, age- and location-matched samples were collected from 25 asymptomatic children
with a positive P. falciparum OptiMAL test (DiaMed) and subsequent positive microscopic
results. Exclusion criteria for all children were a confirmed diagnosis of a coinfection,
malnutrition (mid–upper-arm circumference, <12 cm), or having received antimalarial
treatment within the preceding 2 weeks. The study was approved and ethical clearance was
given by the PNG Medical Research Advisory Committee.
Assessment of P. falciparum infections
Malaria parasites were counted per 200 white blood cells on Giemsa-stained blood films.
Parasite densities were multiplied by 40, to convert values to parasites per microliter [21].
MOIs were determined in P. falciparum–positive samples by msp2 genotyping, as described
elsewhere [22]. Briefly, 30 μL of whole blood was spotted on filter papers (Isocode Stix;
Schleicher & Schuell) and dried for 20 min at 80°C. After washing, msp2 PCR was
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performed directly on the filter papers, and nested PCR products were analyzed by
restriction fragment–length polymorphism, to record the number of infecting strains.
Parasite culture and assessment of the frequency of rosetting
If the parasitemia level was >5000 parasites/μL, parasites from children with severe or mild
malaria were cultured according to standard methods in 10% heterologous AB serum, to
quantify rosetting [23]. Rosettes were defined as the binding of infected RBCs to at least 2
uninfected RBCs and were counted when most parasites were at the late trophozoite/early
schizont stage. An aliquot of culture at 2% hematocrit was stained with ethidium bromide,
and rosettes were counted as a proportion of 200 mature-stage parasites, by use of a
fluorescence microscope. The frequency of rosetting is presented as the percentage of
mature parasite–infected cells found in rosettes.
Isolation of full-length var transcripts and cDNA synthesis
The isolation of full-length var mRNA and reverse transcription (RT) was performed as
described elsewhere [14]. Briefly, total RNA of mainly late ring-stage parasites was
extracted using TRIzol (Invitrogen), in accordance with the manufacturer’s instructions.
RNA was treated with 3 U of RQ1 DNase (Promega). To obtain only full-length var
transcripts, RNA was incubated with 1 pmol of biotinylated oligonucleotides
complementary to the acidic terminal sequence domain. Then, 200 μg of Dynal beads with
M-280 streptavidin was added to the RNA. After washing, RT was performed on the
captured hybrids, which had been primed using 500 ng of hexamers (Invitrogen) and
Sensiscript (Qiagen) reverse transcriptase, in accordance with the manufacturer’s protocol,
in a final volume of 20 μL. An aliquot without reverse transcriptase was used as negative
control. After RT, cDNA was treated with RNase A.
Isolation of genomic DNA
DNA was extracted as described elsewhere [24]. Briefly, 30 μL of full blood was spotted on
filter papers (Isocode Stix; Schleicher & Schuell) and dried for 20 min at 80°C. After
washing, PCR was performed directly on the filter papers.
qPCR
Before qPCR, 1 μL of DNA was amplified in a primary PCR, to increase sensitivity. DNA
was amplified over the var 5′ untranslated region (UTR)–DBL1α in 50-μL volumes with
Advantage cDNA polymerase (Clontech) using 400 nmol/L var group–specific 5′ UTR
forward primers and a degenerated DBL1α reverse primer (table 2). PCR conditions were
94°C for 5 min and 16 cycles (for cDNA) or 14 cycles (for gDNA) of 95°C for 30 s, 52°C
for 1 min, and 64°C for 70 s. Electrophoresis of the primary PCR product showed no visible
band, indicating that the subsequent qPCR did not exceed the linear range. qPCR was
performed over the var group A, B, and C 5′ UTR using the ABI PRISM 7000 Sequence
Detection System (Applied Biosystems). Reactions were done with 5 μL of primary PCR
product in 25-μL volumes with Advantage cDNA polymerase (Clontech) using 250 nmol/L
minor groove binder probes labeled with FAM (Applied Biosystems) and 900 nmol/L
primers for the respective sequences (see table 2). Oligonucleotides were designed
according to alignments of 5′ UTR var gene sequences from the 3D7 genome project
(available at: http://www.plasmodb.org; Joe Smith, Seattle Biomedical Research Institute,
Seattle, WA; personal communication) and var gene sequences from PNG (Genbank
accession numbers AY462581–AY462851). PCR conditions were 94°C for 5 min and 40
cycles of 95°C for 30 s, 54°C for 1 min, and 65°C for 70 s. Electrophoresis of real-time PCR
products was performed to control for single bands and equal size. All cDNA samples were
run in triplicate. All cycle-threshold (CT) values were in the linear range between 15 and 31.
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If all CT values of var group A, B, and C were >31, the sample was discarded and RT-PCR
was repeated. Negative cDNA controls (no reverse transcriptase) of all samples and no-
template controls (NTCs; per 96-well plate) were amplified in parallel. If the NTC was
positive, the plate was discarded. If the negative cDNA control was positive, the sample was
discarded and RT-PCR was repeated. Then, 2.5 ng of gDNA from P. falciparum 3D7 was
amplified in parallel per plate and var group as a positive control and plate calibrator.
Quantification was done using ABI Prism 7000 SDS software (version 1.1; Applied
Biosystems).
Standard curve and relative quantification
Standard curves were linear over a dilution series of 6 log of 10–14 different dilutions, each
in triplicate. The PCR efficiency (E) was calculated using the formula E = 10(1/−slope) – 1.
The mean efficiencies of 3 independent standard curves with high reproducibility were
100% for var group A, 86% for var group B, and 95% for var group C. The lower limit of
detection of the system was <50 copies/mL (data not shown). Relative quantification was
done using the ΔΔCT method (Application Guide; Qiagen) with the following
modifications: CT values were converted to approximate copy numbers using the formula C/
EΔCT, where C is the number of var gene copies in the corresponding var groups A, B, or C
of the plate calibrator (2.5 ng of 3D7 gDNA); E is the real-time PCR efficiency of the
corresponding var group (var group A, 2; group B, 1.86; group C, 1.95); and ΔCT is the
difference in average CT values between the sample and the corresponding var group plate
calibrator. The numbers of var copies in the plate calibrator (C) were estimated by
comparing the real-time PCR oligonucleotide sequences (table 2) and 5′ UTR var gene
alignments (see above). According to these alignments, var group A oligonucleotides
showed <2 mismatches with 6 of 10 var group A genes; var group B oligonucleotides
showed <2 mismatches with 20 of 22 var group B genes, 2 of 4 var group B/A genes, and 4
of 9 var group B/C genes; and var group C oligonucleotides showed <2 mismatches with 7
of 13 var group C genes (var grouping according to Lavstsen et al. [10]). Because of the var-
specific mRNA isolation, no endogenous reference gene could be used. For statistical
analysis, we evaluated proportions of var group transcripts.
To validate our qPCR method, we used RNA from a previous study of var transcription of
parasites selected in vitro for severe malaria and unselected control subjects [25]. This RNA
was quantified by qPCR, and our results agreed with the previous findings—that is, in these
selected parasites, we found a 3.2-fold increase in proportions of var group A transcripts, a
3.6-fold increase in proportions of var group B transcripts, and a 1.6-fold decrease in
proportions of var group C transcripts.
Statistical analysis
Statistical analysis was performed using Stata software (Intercooled Stata, version 8.2;
available at: http://www.stata.com). Levels of var gene transcription were expressed as
transcript proportions of var groups—that is, the number of transcripts of 1 var group as a
proportion of the total transcript numbers for all 3 var groups A, B, and C. Associations
between var group proportions and clinical outcome were analyzed using the Mann-Whitney
U test or the Kruskal-Wallis test. Logistic-regression analyses were performed to calculate
the odds ratio (OR) for disease. ORs were calculated and compared unadjusted or, in
multivariate logistic-regression analyses, with adjustment for parasitemia. Statistical
significance was evaluated using 2-tailed likelihood-ratio tests.
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RESULTS
A total of 65 children were enrolled in the study: 14 with severe malaria, 26 with mild
malaria, and 25 who were asymptomatic (table 1). There was no significant difference in the
age and sex distribution of case patients and control subjects (age and clinical outcome, P = .
6, Kruskal-Wallis test; sex and clinical outcome, P = .72, Fisher’s exact test). Parasite
density showed a significant relationship with clinical outcome (P < .001, Mann-Whitney U
test), but there was no association between clinical outcome and the number of infecting P.
falciparum strains, as determined by msp2 genotyping (table 1).
To test whether the genomic composition of var subgroups in case patients and control
subjects was similar and to exclude primer bias, we quantitatively analyzed var groups A, B,
and C by PCR of genomic DNA. The total amplified var group templates correlated well
with parasite loads of the corresponding children (Spearman’s ρ: var group A, 0.73; var
group B, 0.81; var group C, 0.74; all P < .001). The genomic distribution of the 3 var
subgroups was similar among different clinical outcomes (figure 1B), with 10% overall of
amplified genes belonging to var group A, 76% to var group B, and 14% to var group C.
However, in 14 of 59 samples, fewer var group A genes were amplified, as indicated by
proportions of <5%. This was also the case for var group C genes in 9 of 59 samples.
Furthermore, proportions of var group B genes were only between 50% and 60% in 4
samples. All of these samples were equally distributed among case patients and control
subjects. The corresponding proportions of var group transcripts were also mostly low in
these samples.
Of the 65 children, var group A transcripts were found in 55, var group B transcripts were
found in 62, and var group C transcripts were found in 56. In children with mild and severe
clinical malaria, a significantly higher proportion of var group B transcripts was found,
compared with that in children who were asymptomatic (ORs in table 4 and figure 1A).
Both fever and headache were also significantly correlated with increased var group B
transcription. Proportions of var group B transcripts were not significantly higher in children
with severe malaria, compared with those who had mild malaria.
In 60% of asymptomatic children (15/25), proportions of var group C transcripts were
>10%, and, in 10 of 25 asymptomatic children, more var group C than B transcripts were
found. This is in agreement with observations from culture lines 3D7, NF54, and FCR3S1.2,
in which we also found high proportions of var group C transcripts. Of children with clinical
malaria, only 18% (7/40) had proportions of var group C transcripts >10%. This difference
between asymptomatic children and those with clinical malaria was highly statistically
significant (table 4 and figure 1A). Absolute levels of var group C transcripts were divided
by corresponding genomic DNA levels and resulted in a 15.6-fold increase in the number of
normalized var group C transcripts in asymptomatic children, compared with that in children
with clinical malaria (P = .015, Mann-Whitney U test). There was no significant difference
in numbers of var group C–specific transcripts between children with mild versus those with
severe malaria.
Overall, there was no association between parasite density and the proportion of var groups
on the transcript level (Spearman’s ρ testing the correlation in all 65 children: var group A,
0.06 [P = .62]; var group B, 0.14 [P = .27]; var group C, −0.06[P = .66]). However, in
asymptomatic children, we detected a significant positive association between parasitemia
levels and proportions of var group C transcripts (Spearman’s ρ, 0.51 [P = .013])—more
parasites were detected in children with increased proportions of var group C transcripts
(>0.4). By contrast, in children with clinical disease, a negative association was found
between parasitemia levels and proportions of var group C transcripts.
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Rosetting frequencies were >10% in 33% (10/30) of parasites from children with mild or
severe disease, and var group A transcripts were detected significantly more frequently in
those samples. The median level of var group A transcripts was 3 times that in children who
had lower frequencies of rosetting (P = .047, likelihood ratio from logistic regression)
(figure 1C). The rosetting phenotype was not correlated with the severity of disease, and we
did not observe a significant difference in proportions of var group A transcripts between
children with severe disease and those with mild malaria; we noted only a small,
nonsignificant decrease in proportions of var group A transcripts in children with
asymptomatic malaria (figure 1A and table 1). When we compared var group A transcription
in children with different symptoms of severe malaria, a nonsignificant increase in
proportions of var group A transcripts was found in children with alterations in neurologic
function—that is, the median of these proportions was found in the third quartile (50th–75th
percentile) of var group proportions of all case patients and control subjects.
DISCUSSION
To test whether parasites in children with clinical disease express different var genes, we
used qPCR to compare the proportions of transcripts belonging to var group A, B, and C in
65 children from PNG with severe, mild, and asymptomatic malaria. We found significantly
higher proportions of var group B transcripts in children with clinical malaria (both mild and
severe), compared with those in children who were asymptomatic. Conversely, var group C
transcripts formed a significantly higher proportion of asymptomatic malaria infections. The
major differences in var group transcripts were between asymptomatic and clinical samples.
Quantification of the proportion of var group gDNA by qPCR indicated similar distributions
of var group–specific DNA among samples from children with different clinical outcomes.
Therefore, we conclude that the observed differences in var transcripts are due to
transcriptional regulation during symptomatic malaria and not to primer bias or DNA
composition.
There was no significant difference in proportions of var transcripts between children with
mild and severe malaria. The number of children with severe malaria in the present study
might have been too small for the detection of minor differences, and the analytical power
was further reduced when various conditions caused by severe malaria were analyzed
separately. However, the absence of major differences between mild and severe disease
might indicate that the progression of malaria is a multifactorial continuum in which the
same var gene subset is expressed. The tendency for var group B transcripts to be more
frequent in children with severe malaria suggests that some var group B genes encode for
variants that contribute to sequestration in vital organs.
It has previously been suggested that group A var genes may be responsible for severe
clinical disease [25-27]. We found a tendency toward higher group A var transcription only
in children with alterations in neurologic function, and we observed only a slight increase in
proportions of var group A transcripts in children with mild malaria, compared with those in
asymptomatic children. However, var group A transcripts were significantly more frequent
in children with rosetting parasites, which confirms observations from culture, in which
rosetting was attributed to var group A genes (data not shown). In contrast to studies in
Africa [18, 23], rosetting has been previously shown in PNG not to be correlated with the
severity of disease [28]. CR1 is the main ligand on uninfected erythrocytes for rosetting
[29], and CR1 deficiency occurs in 79% of the Madang population [30]. Low CR1
expression (<150 molecules/cell) was measured in 73% of the children from whom parasite
rosetting frequencies were measured (22/30; data not shown). The rosettes observed in CR1-
deficient hosts might not withstand sheer forces in vivo. This could explain the lack of an
association between disease and rosetting previously described in PNG, and it could also
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explain the lack of an association between severe disease and the up-regulation of var group
A transcripts in these samples.
The prominent presence of parasites transcribing var group B genes in children with clinical
malaria reflects the ability of these parasites to successfully multiply, leading to morbidity. It
has previously been shown that, in clinical malaria, the parasites that predominate express
VSAs that are not recognized by an existing antibody repertoire [31]. In 3D7, var group B
represents the largest var group [10], which could be sufficiently diverse to initially evade
the immune system. The proportional increase in var group C transcripts in asymptomatic
children might indicate the presence of parasites expressing less-pathogenic var variants
with reduced binding abilities.
Nevertheless, we still observed, in 14 of 25 asymptomatic children, more var group B than C
transcripts. In 7 of these children, a small proportion of var group C genes were detected on
the genomic level (<10%), which might indicate that our primers targeted fewer var group C
genes in those parasites. We also noticed that most of these 14 children had lower parasite
loads than other asymptomatic children, so we may have just detected a new parasite
infection preceding clinical symptoms. However, low parasitemia levels may also reflect a
tighter control of parasites expressing var group B variants in hosts who already have a
moderate anti-PfEMP1 antibody repertoire.
Apart from differences in immunogenicity or binding characteristics, the present findings
could also be explained by imprinting processes or specific switching rates inherent to a var
gene or a specific var gene group. For instance, the predominance of var group B expression
in clinical infection might be explained by the high switch-on rate inherent to variants of this
var group. Once their repertoire is exhausted by increasing immunity, var group C variants
might prevail in asymptomatic infections. One could speculate that high switch-off rates are
inherent to var group C genes, resulting in a rapid turnover that impedes effective antibody
responses. Our previous findings in a longitudinal study of a highly dynamic and transient
picture of var transcription in asymptomatic children from PNG support this hypothesis [14].
In conclusion, the present findings emphasize the importance of differential PfEMP1
expression in disease manifestation. Here, we show, to our knowledge for the first time, in a
malaria case-control study conducted in an area of endemicity, that major differences exist
in var expression in vivo between parasites from clinical attacks and asymptomatic
infections, and we have associated the rosetting phenotype with var subgroup A expression.
Further analysis of the var transcripts that we collected will reveal the composition of var
genes within the corresponding var groups and hopefully shed further light on more-virulent
var genes.
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Figure 1.
Box plots of proportions of var groups A, B, and C transcripts. Boxes indicate the median
and quartiles. Vertical lines represent the data range extending to a maximum of 1.5 times
the interquartile range and are not SE bars. Dots indicate the remaining data points. A, Box
plots of clinical outcome (severe, mild, and asymptomatic malaria) and proportions of var
group–specific transcripts (A_, B_, and C_prop, respectively). B, Box plots of clinical
outcome and proportions of var group–specific genomic DNA (A_, B_, and C_propgD,
respectively). C, Box plots of parasites mediating rosetting and proportions of var group-
specific transcripts.
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